Introduction
• Morbidity and mortality following rupture of an intracranial aneurysm have the highest frequency during the 14-day interval immediately following the day of the initial bleed. 1 Rebleeding alone has been the major cause of death among unoperated patients during this two-week period. Patients operated upon within two weeks following the bleed also have the highest morbidity and mortality compared to those operated upon after that interval. 2 
"
5 For protection against an early rebleed prior to surgery, previous reports have described the use of antifibrinolytic agents in the treatment of recent onset subarachnoid hemorrhage (SAH). From March, 1970, through July, 1972, the participants of the Cooperative Aneurysm Project pursued a study so formulated that antihypertensive and antifibrinolytic drugs were used randomly, either alone or in combination.
8 -' In that study, mortality and morbidity during the 14-day period were significantly improved with antifibrinolytic therapy alone as compared to the group treated with antihypertensive medication alone or the combination of antihypertensive and antifibrinolytic medication. Following that study, all patients from every participating institution who entered the study had antifibrinolytic therapy initiated within seven days, a treatment which was continued until 14 days following the bleed. The primary objective was the prevention of rebleeding. With neurological and medical conditions stabilized at 14 days, a decision was made for definitive surgical or continued medical therapy following that interval. The following report describes the preliminary results of that study. Followup data will be presented in a subsequent report.
Treatment Management
From October, 1972, through June, 1974, 471 patients were treated with epsilon-aminocaproic acid (EACA) or tranexamic acid during a period of 7 to 14 days following the bleed. Treatment was initiated following the clinical diagnosis of a ruptured intracranial aneurysm with the finding of grossly bloody spinal fluid as determined by lumbar puncture and with roentgenographic determination of one or more intracranial aneurysms. The protocol stipulated that laboratory studies such as a complete blood count, urinalysis, platelet determination, fibrinogen level, and a serum biochemical profile be completed prior to treatment. Twenty-four or 36 gm of EACA were given by continuous
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drip intravenously in 800 to 1,000 ml of 5% dextrose in water every 24 hours. The dosage of EACA was monitored by the streptokinase clot lysis time.
8 -• After three to ten days of intravenous therapy, EACA was given orally every two hours until the end of the 14-day interval following the last bleed. At that time a decision was made for the patient to undergo surgery or be continued on medical therapy. Tranexamic acid, a more potent antifibrinolytic agent, was given by two participating centers in dosages of 8 to 16 gm per 24 hours, initially by the intravenous route, followed by the oral preparation until the end of the treatment period. No antihypertensive medications were administered and no salicylates were prescribed. In instances where the blood pressure was excessively elevated, such patients were removed from the study. From a total of 502 protocols submitted to the Central Registry (table 1) , 471 remained for detailed analysis.
Clinical Material
Among the 471 patients, 100 had an aneurysm on the intracranial portion of the internal carotid artery, 83 had one on the middle cerebral distribution, 171 on the anterior cerebral-anterior communicating complex, 27 on the vertebrobasilar system, and in 90 patients more than one aneurysm was seen in the cerebral angiogram (table 2) . Thirty-one patients were disqualified for various reasons (table 3) which included those who had a craniotomy prior to the end of the 14-day treatment period.
Forty-eight percent of patients had antifibrinolytic therapy initiated within two days following the last bleed (87.4% within five days). On the day of entry into the study, the neurological condition was specified for each patient (table 4) . The distribution of patients in these conditions was correlated with the degree of vasospasm as visualized by cerebral angiography. Twenty-six percent (82 of 317) who were in good neurological condition (Grades 1 and 2) had localized and diffuse vasospasm, and 33% of those in poor condition (Grades 3 to 6) had vasospasm (P = 0.09).
Sixty-one percent of the patients were women. Interestingly, for all patients 50 years of age and over, 69% (166 of 240) were females, whereas in the group below age 50, 52.4% were women. The distribution of men above and below age 50 was nearly the same. The majority of patients were women among three aneurysm sites, namely, internal carotid, vertebrobasilar, and multiple locations (table 5) . Although the proportion of men and women with an aneurysm on the middle cerebral and anterior cerebral complex was similar, there were more women than men in the entire group. Among the 62 female patients with multiple aneurysms, 61.3% had one of their intracranial aneurysms on the internal carotid artery.
Overall medical condition was assessed on the day antifibrinolytic therapy was initiated. A total of 44.6% were in good condition, 45.4% in fair condition, and 10% in poor and prohibitive condition (table 6). For patients in fair, poor, and prohibitive medical condition, 38% had mean blood pressures below 100 mm Hg; 66% had mean pressures above 100 mm Hg. In contrast, patients in good medical condition had nearly equal distribution of patients with mean blood pressure above and below 100 mm Hg, whereas patients in fair to prohibitive medical conditions had a higher association with elevated blood pressures (P < 0.001).
Results
Determination of mortality and proved rebleeds during the 14-day interval following the last bleed was the primary objective in this study. Mortality at the end of 14 days was 11.6%. Proved rebleed rate (as determined by lumbar puncture or postmortem examination) was 12.7%. A proved rebleed was the major cause of death in 27 patients (table 7). The highest proportion of these deaths occurred during the second week after the bleeding event. Analysis of the interval to rebleed following the initial episode which prompted hospitalization reveals that 2.5% rebled within five days, 7.4% within eight days, and 10.4% within 11 days. A similar time distribution was observed for patients who died following progressive decline from the direct cerebral effects of the original bleed (14 of 17 deaths). Most recurrent hemorrhages (61.7% or 37 of 60) occurred between the sixth and eleventh days following the initial bleed (table 8) . This was the main reason for the high number of deaths reported during the 6-day through 14-day period. tifibrinolytic medication, the interval required to reach a proper antifibrinolytic effect was usually three to five days. 8 Analysis of the interval between the beginning of antifibrinolytic medication and recurrent hemorrhage reveals that 45.4% of proved and suspected rebleeds occurred prior to the day proper antifibrinolytic effect was reached.
ANALYSIS OF CLINICAL CHARACTERISTICS AS IILATID TO

MORTALITY AND MORMDITY
Various characteristics in patients with SAH potentially influence the outcome (death and/or rebleeding from a ruptured intracranial aneurysm). For this discussion, several variables such as age, sex, aneurysm site, neurological and medical conditions, blood pressure, and vasospasm were correlated with mortality and proved rebleeds during the 14-day interval.
For patients below age 50, 9.2% died; 10.9% rebled. For those aged 50 or above, 13.7% died (P > 0.05) and 14.2% rebled (P > 0.05). Sex distribution revealed that 9.3% of deaths occurred in men and 13.2% in women (P > 0.05); the rebleed rate was 6.5% for men and 16.7% for women (P < 0.001). Mortality distribution for each aneurysm site was similar to the rebleed rate with the exception of patients with an in-TAILI 4 •Definition of neurological condition: 1 -symptom-free, 2 = minor symptoms (headache, meningeal irritation, diplopia), 3 -major neurological deficit but fully responsive, 4 -impaired state of alertness but capable of protective or other adaptive responses to noxious stimuli, 5 = poorly responsive but with stable vital signs, 6 = no response to address or shaking, nonadaptive response to noxious stimuli, and progressive instability of vital signs. ancurysm on the internal carotid or anterior cerebral distribution had the highest mortality and rebleed rate. Neurological condition on the day of allocation to treatment was clearly related to mortality. For patients with impaired state of mental alertness beyond a few days following the last bleed, mortality was proportionately greater than the rebleed rate (table 10) . Average mortality for patients in Grades 1 and 2 was 6.9% (22 of 317), whereas for patients in poor condition (Grades 3 through 6) mortality was 21.4% (33 of 154, P < 0.001). Average rebleed rate was 11.3% for the former group and 15.6% for the latter (P > 0.05).
Distribution of Patients With Various Degrees of Vasospasm for Each Neurological Condition
Medical condition also was related to mortality and rebleed rate. Patients in poor and prohibitive medical conditions had mortality and rebleed rates three times that seen in patients classified as being in good and fair conditions. Those in good and fair conditions had a combined mortality of 9.4% (40 of 424), and a rebleed rate of 11.1% (table 11) . Mortality in poor and prohibitive conditions combined was 31.9% (15 of 47, P < 0.001) and had a proved rebleed rate of 27.7% (13 of 47, P < 0.001). Cerebral vasospasm (as demonstrated by cerebral angiography) was categorized as localized or diffuse. Localized vasospasm was interpreted as a decrease in intra-arterial diameter of 1 to 3 cm over the proximal portions of the internal carotid, middle cerebral, anterior cerebral, or vertebrobasilar arteries. Diffuse vasospasm was regarded as decreased diameter of the internal carotid artery and all its main branches, either ipsilateral or contralatcral to the aneurysm.
TAILI i
Distribution of Patients in Various Medical
Rebleed rate was unrelated to the degTee of vasospasm. However, the proportion of deaths among patients with diffuse vasospasm was twice that among those without vasospasm (22% versus 9.2%, table 12). This finding was highly significant (P = 0.013). Therefore, pathophysiologic changes associated with cerebral vasospasm can produce sufficient structural and/or metabolic damage to cause severe degrees of localized or widespread deterioration in neuronal function.
Mortality and rebleed rates were directly related to increments in mean blood pressure as measured on the day of allocation to treatment. Patients with average mean blood pressures of 110 mm Hg or below had an average mortality of 8.3% (23 of 276), and a rebleed rate of 10.5% (table 13) . Patients with average mean blood pressures above 110 mm Hg had a mortality of 16.1% and rebleed rate of 16.1%. These results for mortality and rebleed rates below and above a mean blood pressure of 110 mm Hg were significant for mortality rate (P = 0.015) but not for rebleed rate (P = 0.103).
TAIL! I
Distribution of Rebleeds During 14-Day Interval Following Last Bleed
SIONS AND SYMPTOMS O t S U V I D DURING THITIIATMINT PHIOD
A list of 30 items were monitored and recorded in the treatment protocol. The list of these various conditions (table 14) with the percent of total patients affected in each condition reveals the broad spectrum of medical disorders affecting patients with SAH. The most frequent condition was diarrhea (24.3%) which was drug-related (oral epsilon-aminocaproic or tranexamic acid). Patients who developed ischemic neurological deficit acquired a hemiparesis, hemiplegia and/or aphasia. In our opinion these were not drug-related events. All the remaining conditions also were considered to be unrelated to drug therapy with the exception of the dermatological problems. These were difficult to delineate because of other analgesic and anti-inflammatory medications prescribed in conjunction with antifibrinolytic therapy.
Discussion
Hemorrhagic cerebrospinal fluid from a ruptured intracranial aneurysm is associated with a marked increase in fibrinolytic activity. This is caused by a rapid increase in the amount of fibrinolytic precursor (plasminogen). 10 Epsilon-aminocaproic acid and tranexamic acid are known fibrinolytic inhibitors. Recent studies suggest that the mechanism of these agents may be through inhibition of the synthesis in the plasminogen-plasmin system.
TABU 10
Distribution of Mortality and Rebleed Rate by Neurological Condition
11
- 12 The mechanism for prevention of recurrent hemorrhage following a recently ruptured intracranial aneurysm is assumed to be an inhibition of this fibrinolytic mechanism. The use of antifibrinolytic therapy with recently ruptured intracranial aneurysm has been associated with favorable results upon recurrent rebleed rate and mortality prior to definitive surgery. This combined medical-surgical approach toward treatment of recently ruptured intracranial aneurysms was pursued in this study.
Several clinical characteristics of patients with SAH were related to mortality and rebleed rates during the two-week treatment period. Female patients with an internal carotid aneurysm had the poorest survival. Most rebleeds occurred between the sixth and eleventh days following the last bleed. On the average, the rebleed rate was higher among women than men and, therefore, increased mortality was reported among women, although the differences did not reach statistical significance. Patients in poor neurological condition had a higher mortality than those in good condition because they had more pulmonary or genitourinary tract infections and were more likely to die from the direct cerebral effects of the original bleed. No significant difference in rebleed rate was seen between patients in good and poor neurological conditions. Rebleed rate was unrelated to vasospasm, •See text for definition. Numbers in parentheses are percent. T w o additional patients had insufficient blood pressure information available. Numbers in parentheses are percent.
TA1LI11
Distribution of Mortality and Rebleed Rate for Patients With Various Degrees of Vasospasm
TAIL!11
Distribution of Blood Pressure
but mortality was higher among those with severe localized and diffuse vasospasm. Vasospasm neither promoted nor improved the rebleed rate, yet the biochemical and structural changes were responsible for the production of edematous and/or ischemic changes to such a degree that mortality was appreciably higher in patients with vasospasm.
Patients with mean blood pressure above 110 mm
Hg at the onset of therapy had increased mortality and rebleed rates during the 14-day period compared with those below 110 mm Hg. Mortality was particularly low (3%) in the group with mean blood pressure below 90 mm Hg. A number of factors may be responsible for elevated blood pressure, including stress, preexisting essential hypertension, degree of increased intracranial pressure, fluid balance, drugs, and the extent of infarction or size of the hematoma. In a previous investigation conducted by the participants of the Cooperative Aneurysm Study, patients with SAH were randomly allocated to one of four treatment programs, namely, regulated bedrest, druginduced hypotension, carotid ligation, and intracranial surgery. For patients allocated to regulated bedrest within seven days following the last bleed, 13 both mortality and rebleed rates at 14 days were 20.9%. Rebleed rate was similar between each aneurysm site. Twenty percent of the patients with an internal carotid aneurysm rebled, 16.7% with a middle cerebral aneurysm, and 21.8% with an aneurysm on the anterior cerebral complex. Mortality at 14 days was highest for the internal carotid group (36%). Patients Overall mortality and rebleed rates were significantly higher (P < 0.05) in those patients compared with the group described in this report who received antifibrinolytic therapy. In a similar group of patients treated by intracranial surgery within 14 days following the last bleed, 44.5% died following operation. In those who were allocated to drug-induced hypotension, 21.7% died and 16.9% had a proved rebleed within the 14-day interval. Therefore, comparison of these groups of patients with those who were treated with antifibrinolytic therapy during a 14-day period reveals that the latter group had the best survival and rebleed rates.
TAIL! 1 4
Distribution of Signs or Symptoms Observed During the Treatment Period for the 464 Protocols in which this Information Was Received at the Central Registry
Considerable attention has been devoted toward the complicating events which are said to be attributed to the use of antifibrinolytic agents. Arteriopathic changes as visualized by cerebral angiography (without histological verification), 14 and segmental thrombosis of cerebral vessels 15 ' 18 have been said to result from antifibrinolytic therapy. An extensive review of potential complications associated with the use of epsilon-aminocaproic acid in non-neurological disorders has been reported. 17 A detailed list of potential conditions or symptoms was monitored in this Study while antifibrinolytic therapy was administered. The treatment protocols provided especially for this information. The most frequent drug-related condition reported was diarrhea in 24.3% of the patients. In only 2.4% was this complication severe. Hemiparesis was reported in 17% and hemiplegia in 11.2%. Particular attention was given to certain hematologic factors such as clotting derangements, bleeding time abnormalities, evaluation of certain coagulation factors, and occurrence of pulmonary embolism. So-called clotting derangements were reported in three patients; one had an elevated partial thromboplastin time of 88 seconds (with a control of 37), one patient had a prothrombin time of eight seconds (with a control of 12) and in the third patient no information was specified. Coagulation factor abnormalities were classified as minor in each of two patients. These were manifested in one patient as a mild gastrointestinal hemorrhage; the other had marked increase in serum fibrinogen and platelet count without clinical manifestations. Two patients developed pulmonary emboli. One was subclinical, that is, the pathological report described multiple small lung emboli, and in the other patient cardiorespiratory difficulties alerted the attending physician to this diagnosis. The condition was confirmed by a radioactive lung scan. Both of these patients were poorly responsive as a result of the intracranial event, and one was excessively obese as well. Among the 471 patients, these reports show clearly that the necessary risk in the administration of antifibrinolytic drugs was minimal in comparison to its therapeutic effectiveness.
Included in the protocols was a question relating to the overall clinical course during therapy with regard to whether the clinical condition of the patient improved, remained the same, or deteriorated. Comparison of improvement rates in overall clinical condition in the previous Phase III study 7 revealed that among patients who received antifibrinolytic medication alone, 45.9% improved, whereas of those who received antihypertensive agents alone, 30.4% improved, and in the group treated with antifibrinolytic therapy and antihypertensive medication only 23.8% improved. In the present study, 42.3% improved, 30.6% became worse, and the remainder had no change in their condition during antifibrinolytic therapy. Although these data were basically judgment decisions made by the attending physicians, the information is useful and practical. Rather than using one specific measurement in stating whether or not a patient improves or deteriorates, in this evaluation the global perspective of each patient's clinical status was reviewed.
Patients who received epsilon-aminocaproic acid intravenously in a dosage of 36 gm per day appeared to do better than those who received a lower or similar dosage by the oral route. Unpublished preliminary observations 18 reveal there is considerable variability in absorption rates and urinary excretion patterns following the administration of EACA by the oral route. This factor by itself may have considerable effect upon the amount of antifibrinolytic activity present in the serum at a particular time in any one patient.
Since the introduction of antifibrinolytic agents in patients with recently ruptured intracranial aneurysm, the dosage of epsilon-aminocaproic acid has been increased from 4 gm every four hours orally to 36 gm per day by the intravenous route. The best results are achieved when patients are treated with 36 gm per day intravenously (preferably through administration of 18 gm of EACA in 400 ml of 5% dextrose in water every 12 hours in a continuous intravenous drip). This approach should be used for ten days followed by oral therapy in the form of 3 gm every two hours. This dosage may be maintained until surgery is performed. When a surgical procedure is not performed, antifibrinolytic therapy can be continued until 21 days following the last bleed, when the dosage should be decreased gradually over the next week, by decreasing the daily amount to 24 gm per day (2 gm every two hours) for three days, followed by 1 gm every two hours for three days, and then discontinuation. In the author's experience (D.W.N.), this schedule has been the most effective manner of administration of EACA for patients with recently ruptured intracranial aneurysm.
Without such assistance this cooperative interinstitutional clinical study would not have been possible.
